KR20220046549A - 거대고리 카이네이스 억제제의 다형체 - Google Patents
거대고리 카이네이스 억제제의 다형체 Download PDFInfo
- Publication number
- KR20220046549A KR20220046549A KR1020227001994A KR20227001994A KR20220046549A KR 20220046549 A KR20220046549 A KR 20220046549A KR 1020227001994 A KR1020227001994 A KR 1020227001994A KR 20227001994 A KR20227001994 A KR 20227001994A KR 20220046549 A KR20220046549 A KR 20220046549A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- ret
- crystalline
- powder
- polymorphic form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863493P | 2019-06-19 | 2019-06-19 | |
| US62/863,493 | 2019-06-19 | ||
| US202062959940P | 2020-01-11 | 2020-01-11 | |
| US62/959,940 | 2020-01-11 | ||
| US202063036102P | 2020-06-08 | 2020-06-08 | |
| US63/036,102 | 2020-06-08 | ||
| PCT/US2020/037892 WO2020257169A1 (en) | 2019-06-19 | 2020-06-16 | Polymorphs of a macrocyclic kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220046549A true KR20220046549A (ko) | 2022-04-14 |
Family
ID=74040102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227001994A Ceased KR20220046549A (ko) | 2019-06-19 | 2020-06-16 | 거대고리 카이네이스 억제제의 다형체 |
Country Status (15)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336774B (zh) * | 2021-06-25 | 2023-05-23 | 江南大学 | 作为trk抑制剂的取代的手性二芳基大环化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| RU2732405C2 (ru) * | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| BR112018000297A2 (pt) * | 2015-07-06 | 2018-09-04 | Tp Therapeutics Inc | polimorfo de macrociclo de diarila |
| WO2017015367A1 (en) * | 2015-07-21 | 2017-01-26 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| CA3069554A1 (en) * | 2017-07-14 | 2019-01-17 | Glaxosmithkline Intellectual Property Development Limited | Inhibitors of leucine rich repeat kinase 2 |
| RS63787B1 (sr) * | 2017-12-19 | 2022-12-30 | Turning Point Therapeutics Inc | Makrociklična jedinjenja za lečenje bolesti |
-
2020
- 2020-06-16 WO PCT/US2020/037892 patent/WO2020257169A1/en not_active Ceased
- 2020-06-16 MX MX2021015756A patent/MX2021015756A/es unknown
- 2020-06-16 US US17/618,060 patent/US20220411439A1/en not_active Abandoned
- 2020-06-16 JP JP2021575515A patent/JP2022537385A/ja not_active Withdrawn
- 2020-06-16 AU AU2020294627A patent/AU2020294627A1/en not_active Abandoned
- 2020-06-16 PH PH1/2021/553174A patent/PH12021553174A1/en unknown
- 2020-06-16 KR KR1020227001994A patent/KR20220046549A/ko not_active Ceased
- 2020-06-16 EP EP20826665.0A patent/EP3986413A4/en not_active Withdrawn
- 2020-06-16 CA CA3143043A patent/CA3143043A1/en active Pending
- 2020-06-16 BR BR112021025786A patent/BR112021025786A2/pt not_active Application Discontinuation
- 2020-06-16 PE PE2021002184A patent/PE20220135A1/es unknown
- 2020-06-16 CN CN202080044953.1A patent/CN114025765A/zh active Pending
- 2020-06-19 TW TW109120778A patent/TW202115090A/zh unknown
-
2021
- 2021-12-14 IL IL288982A patent/IL288982A/en unknown
-
2022
- 2022-01-19 CO CONC2022/0000405A patent/CO2022000405A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553174A1 (en) | 2022-08-01 |
| WO2020257169A1 (en) | 2020-12-24 |
| MX2021015756A (es) | 2022-01-27 |
| AU2020294627A1 (en) | 2022-02-17 |
| IL288982A (en) | 2022-02-01 |
| PE20220135A1 (es) | 2022-01-27 |
| JP2022537385A (ja) | 2022-08-25 |
| BR112021025786A2 (pt) | 2022-02-01 |
| CA3143043A1 (en) | 2020-12-24 |
| TW202115090A (zh) | 2021-04-16 |
| EP3986413A4 (en) | 2023-06-14 |
| CN114025765A (zh) | 2022-02-08 |
| CO2022000405A2 (es) | 2022-04-29 |
| US20220411439A1 (en) | 2022-12-29 |
| EP3986413A1 (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7212713B2 (ja) | ジアリール大環状多形 | |
| US9890168B2 (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| JP2019518776A (ja) | Egfr阻害剤としてのアニリンピリミジン化合物の結晶 | |
| CN110461847A (zh) | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 | |
| WO2012136099A1 (zh) | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 | |
| HU227569B1 (en) | N-(3-ethynylpheyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate and pharmaceutical compositions containing the same | |
| US20220411439A1 (en) | Polymorphs of a macrocyclic kinase inhibitor | |
| CN114599655B (zh) | 咪唑烷酮类化合物及其制备方法与应用 | |
| CN114599656A (zh) | 咪唑烷酮类化合物及其制备方法与应用 | |
| CN118652239A (zh) | 一类egfr别构抑制剂的合成及其用途 | |
| JP2023503133A (ja) | Cd73を標的とするスルホンアミド化合物およびアデノシン受容体 | |
| HK40059224A (en) | Diaryl macrocycle polymorph and method for preparing the same | |
| HK40059224B (en) | Diaryl macrocycle polymorph and method for preparing the same | |
| HK1254492B (en) | Diaryl macrocycle polymorph | |
| HK1260821B (en) | Crystals of aniline pyrimidine compound serving as egfr inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |